(Q46534674)

22 December 2017

title

Nutritional intervention to prevent weight gain in patients commenced on olanzapine: a randomized controlled trial (English)

1 reference

22 December 2017

1 reference

2

1 reference

22 December 2017

Sherryn Evans

0 references

author name string

Sherryn Evans

series ordinal

1

1 reference

22 December 2017

Sally Higgins

series ordinal

3

1 reference

22 December 2017

publication date

1 June 2005

1 reference

22 December 2017

Australian and New Zealand Journal of Psychiatry

published in

1 reference

22 December 2017

volume

39

1 reference

22 December 2017

issue

6

1 reference

22 December 2017

page(s)

479-486

1 reference

22 December 2017

Use of antipsychotic medications in Australia between July 1995 and December 2001.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Olanzapine: weight gain and therapeutic efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Nizatidine for prevention of weight gain with olanzapine: a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Effect of amantadine on weight gain during olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Panic disorder associated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Orlistat in the treatment of psychopharmacologically induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

The effect of orlistat on plasma levels of psychotropic drugs in patients with long-term psychopharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Management of weight gain associated with antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

Options for pharmacological management of obesity in patients treated with atypical antipsychotics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

A program for treating olanzapine-related weight gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

The Effects of an Educational Intervention on Antipsychotic‐Induced Weight Gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1440-1614.2005.01607.X

10.1111/J.1440-1614.2005.01607.X

21 January 2018

Identifiers

DOI

1 reference

22 December 2017

1 reference

22 December 2017